RAD51AP2, a novel vertebrate- and meiotic-specific protein, sharesa conserved RAD51-interacting C-terminal domain with RAD51AP1/PIR51 by Kovalenko, Oleg V. et al.
RAD51AP2, a novel vertebrate- and meiotic-specific protein shares a conserved
RAD51-interacting C-terminal domain with RAD51AP1/PIR51
Oleg V. Kovalenko, Claudia Wiese1 and David Schild1,*
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, MA,
02115, USA; 1 Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA
94720, USA
* To whom correspondence should be addressed. Tel: +1 510 486 6013; Fax: +1 510 486 6816;
E-mail: dschild@lbl.gov
2ABSTRACT
Many interacting proteins regulate and/or assist the activities of RAD51, a recombinase which
plays a critical role in both DNA repair and meiotic recombination. Yeast two-hybrid screening
of a human testis cDNA library revealed a new protein, RAD51AP2 (RAD51 Associated Protein
2), that interacts strongly with RAD51. A full-length cDNA clone predicts a novel vertebrate-
specific protein of 1159 residues, and the RAD51AP2 transcript was observed only in meiotic
tissue (i.e. adult testis and fetal ovary), suggesting a meiotic-specific function for RAD51AP2. In
HEK293 cells the interaction of RAD51 with an ectopically-expressed recombinant large
fragment of RAD51AP2 requires the C-terminal 57 residues of RAD51AP2. This RAD51-
binding region shows 81% homology to the C-terminus of RAD51AP1/PIR51, an otherwise
totally unrelated RAD51-binding partner that is ubiquitously expressed. Analyses using
truncations and point mutations in both RAD51AP1 and RAD51AP2 demonstrate that these
proteins use the same structural motif for RAD51 binding. RAD54 shares some homology with
this RAD51-binding motif, but this homologous region plays only an accessory role to the
adjacent main RAD51-interacting region, which has been narrowed here to 40 amino acids. A
novel protein, RAD51AP2, has been discovered that interacts with RAD51 through a C-terminal
motif also present in RAD51AP1.
3INTRODUCTION
The eukaryotic RAD51 gene was first identified in baker’s yeast through analysis of mutations
that result in recombination deficiency and sensitivity to DNA-damaging agents (1). Genetic
studies in yeast demonstrated that the RAD51 protein plays a prominent role in both mitotic and
meiotic recombination, and in DNA repair (2-5). In meiosis, RAD51 is thought to promote
homologous chromosome synapsis and interhomolog recombination (6-8). Sequence and
structural analysis of the yeast and mammalian RAD51 proteins revealed extensive similarity to
the key bacterial recombinase RecA. The extensive biochemical analysis of yeast and human
RAD51 proteins highlighted the functional similarities between these proteins and the RecA
protein (9-12). The RAD51  gene in vertebrates has been shown to be essential for cell
proliferation. Mice with a targeted disruption of the RAD51 gene die early during embryogenesis
(13,14).  Furthermore, repression of human RAD51 is lethal in a chicken rad51-/- DT40 cell lines
expressing an inducible HsRAD51, probably due to the accumulation of chromosome breaks,
supporting a role for HsRAD51 in the repair of DNA breaks arising during replication (15).
The normal activity of RAD51, both in homologous recombinational DNA repair in mitotic
cells and in meiotic recombination, necessitates its physical interactions with a number of other
proteins. Indeed, mammalian RAD51 has been shown to interact in vitro and/or in vivo with the
recombination proteins RAD52 and RAD54 (16,17), the tumor suppressors TP53 and BRCA2
(18-23), the protein kinase c-ABL (24,25), the SUMO-1-conjugating enzyme UBC9 (26-28), the
RAD51 paralogs XRCC3 and RAD51C (29,30), MDC1 (mediator of DNA damage checkpoint)
(31), RPA (replication protein A) (32,33), CHK1 (34), nucleolin (35) and several other proteins
(for review see (12,36)). The interactions of RAD51 with TP53, RPA and the BRC repeats of
BRCA2 are relatively well understood (see Discussion). Much remains to be learned about other
RAD51 protein-protein interactions, and clearly further biochemical and genetic analyses of
these interactions will facilitate our understanding of the function and regulation of the RAD51
protein.
In a previous study, we identified a novel RAD51-interacting protein, RAD51AP1/PIR51
through a yeast two-hybrid human cDNA library screen (37). (Please note: the HUGO committee
on nomenclature has renamed PIR51 as RAD51AP1 for RAD51 Associated Protein 1.) Using the
same approach, Mizuta et al. (19) independently identified the mouse Rad51ap1 homolog
(originally called Rab22). The interaction of human and mouse RAD51AP1 with RAD51 was
confirmed by in vitro experiments, and in vivo co-localization of mouse RAD51AP1 to RAD51
foci was shown using ectopical overexpression of tagged constructs (19,37). In the current study,
we present data on the identification of another novel human protein, RAD51AP2 (RAD51
Associated Protein 2), which interacts strongly and specifically with human RAD51.
Interestingly, human RAD51AP2 expression is detected only in adult testis and fetal ovary,
which suggests that its gene product may play a role in RAD51-mediated meiotic recombination.
Moreover, we have identified a common motif present in both RAD51AP2 and RAD51AP1 that
mediates their interaction with RAD51. A sequence that shares some homology with this motif is
also present in the RAD54 protein, but seems to play at most only a minor role in the interaction
of RAD54 with RAD51.
4MATERIALS AND METHODS
Two-hybrid system
The Gal4-based yeast two-hybrid system was essentially as described previously (37). All the
vectors and yeast strains were obtained from Clontech. To screen for RAD51-interacting
proteins, a human testis cDNA library in vector pACT2 was used. Yeast strain HF7c was first
transformed with a RAD51 bait construct, pEG918, followed by the library DNA. Interacting
clones were selected as His+ transformants, and were subsequently tested for activation of lacZ
reporter in strain SFY526. The clone containing the partial RAD51AP2 gene sequence, whose
protein product interacts with RAD51, was designated p23-1. Vectors pGBT9 and pGADGH
were used to make additional two-hybrid constructs for human RAD51AP1, RAD51AP2,
RAD54 and DMC1, and for S. cerevisiae RAD51. Vector pGBKT7 was used to make the
RAD51AP2-C33 construct for the experiment in Fig. 5C. For yeast two-hybrid analyses of some
of the RAD51AP1 and RAD51AP2 mutants and for the RAD54 truncation analyses, the yeast
strain Y190-ura- was used (29). The QuikChange II Site-directed Mutagenesis Kit (Stratagene)
was used for mutagenesis, and each mutated/truncated construct was sequenced across the
complete insert.
Cloning of the full-length RAD51AP2 ORF
To amplify the full length RAD51AP2 ORF, primers were designed from the 5´-UTR (5´-
GCGGAATTCGACAGATCCTTTCCATTCGCTGTC-3´; the underlined EcoRI site was added
f o r  s u b c l o n i n g )  a n d  f r o m  t h e  3 ´ - U T R  ( 5 ´ -
CGCGGATCCATGCCCCAAACCCCCAAGCTGGAAGAAC-3´; the underlined BamHI site
was added for subcloning).  GenBank contains 3 EST clones (loci DB088408, DB096210, and
DB449196) that are reported to be full length and have sequence data from the 5´ end of the
RAD51AP2 cDNA. Since these clones were not available, we used their partial GenBank
sequence data from the 5´-end and our own DNA sequence data for the 3´-end to design primers
to amplify the entire ORF from Marathon-Ready total cDNA from human testis (Clontech).
Since no PCR product was observed using these two primers, two additional internal primers
were designed for use in combination with the original primers to separately amplify the 5´-
reg ion  and  the  3 ´ - reg ion  o f  the  R A D 5 1 A P 2  ORF (5 ´ -
CGTAACTGTCCAGACATTCTGCTTCCTCCC-3´ was used in combination with the original
5´ primer, and 5´-GAAAATGACTACCCATCACTCAGTAGCC-3´ was used in combination
with the original 3´ primer). PCR was performed with high-fidelity Pfu DNA polymerase
(Stratagene) using 30 cycles. The resulting two PCR products overlap by ~100 bp, and each
product includes the unique PstI site in the middle of the RAD51AP2 ORF. Following restriction
digestion, the EcoRI to PstI fragment from the 5´-end and the PstI to BamHI fragment from the
3´-end were each subcloned into the EcoRI to BamHI sites of a single pBluescript SK+ vector,
reconstituting the full-length RAD51AP2 ORF.  The complete DNA sequence of the insert in this
plasmid (pDS443) was determined for both stands.
Northern analysis of the RAD51AP2 expression
A human multiple tissue Northern blot II (Clontech) was used to analyze RAD51AP2 mRNA
expression. The sequence of the RAD51AP2 insert in clone p23-1 was amplified by PCR.  The
resulting fragment was labeled with α-32P-dCTP by random priming and used as the
hybridization probe following conditions suggested by Clontech.
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PCR was used to determine if the RAD51AP1 and RAD51AP2 transcripts are present in cDNA
samples from 16 different adult human tissues (Clontech), 5 different fetal human tissues
(BioChain) and 7 different human cell lines (Clontech). The PCR primers used for RAD51AP1
were  AP1-5´ :  5´GATGACAAGCTCTACCAGAGAGAC3´ and AP1-3´ :
5´CTTGCTTTCAGCTGAAGGACTGCG3´, and these amplify a 630 bp fragment. The primers
for RAD51AP2 were AP2-5´: 5´CTGGTCTGAGTGAAGGGAATGATG3´ and AP2-3´:
5´GCGGTCGTACTCTTGAAATGCCATG3´, and these amplify a 570 bp fragment. For each
primer pair, the two different primers were from different exons, thus avoiding an possible
problems with contaminating genomic DNA, since this DNA would result in a much larger PCR
product. PCR was performed using Taq polymerase, with 35 cycles of 50o C 60 s, 72o C 120 s
and 94o C 60s.
Interaction of RAD51 and RAD51AP2 proteins in mammalian cells
To produce the RAD51AP2 protein in mammalian cells, the sequence encoding the 293-aa
RAD51AP2 polypeptide from p23-1 was subcloned into vector pCGT (obtained from Dr. H.
Zhang, Yale University) as a fusion with a T7 epitope, producing plasmid pOK80. Also,
RAD51AP2 sequence lacking its last 57 amino acids (RAD51AP2-ΔC57) was cloned into
pCGT, producing plasmid pOK90. Fortuitously, the vector pCGT used for cloning contained the
sequence of human herpesvirus Vmw65 protein. Cloning of RAD51AP2 sequences into this
vector placed the inserts upstream of the Vmw65 sequences, effectively eliminating expression
of the latter. Thus, when used as a control in transfection experiments, vector pCGT produced
the T7-tagged 65-kDa Vmw65 polypeptide, whereas plasmids pOK80 and pOK90 produced only
the expected T7-tagged RAD51AP2 protein fragments.
For transient transfection and co-immunoprecipitation experiments, pCGT, pOK80 and
pOK90 were introduced into cultured human HEK293 cells using the calcium phosphate
procedure, and cells were incubated for 36 hrs.  In some experiments, DNA damage was
introduced to transfected cells 3 hrs before the cells were harvested by adding 0.01%
methylmethane sulfonate or 0.5 µg/ml mitomycin C to the medium. As a control, cycloheximide,
a protein synthesis inhibitor, was added at 10 µg/ml in these experiments. After harvest, cells
were lysed in buffer containing 20 mM Na-phosphate (pH 7.4), 150 mM NaCl, 0.5% Nonidet P-
40, and a cocktail of protease inhibitors (Roche) for 20 min on ice. Lysates were used for
immunoprecipitation with monoclonal antibody directed against the T7 tag (Novagene) followed
by protein A-agarose beads. The beads were washed several times with lysis buffer and the
immunoprecipitated material was analyzed by SDS-PAGE followed by immunoblotting with
anti-T7 and anti-RAD51 antibodies. Secondary anti-mouse or anti-rabbit antibodies were
conjugated with alkaline phosphatase, and detection was carried out with NBT (nitroblue
tetrazolium chloride) and BCIP (5-bromo-4-chloro-3-indolylphosphate p-toluidine salt)
chromogenic substrates (Life Technologies), or with the more sensitive Renaissance®
chemiluminescence reagent (NEN Life Science Products). Bands produced on an X-ray film
after chemiluminescence detection were scanned and quantitated using a Molecular Dynamics
densitometer.
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Isolation of the human RAD51AP2 gene
Using the human RAD51 protein as a bait, a yeast two-hybrid screen of a human testis cDNA
library resulted in the isolation of an ~1.2-kbp insert encoding 321 amino acids, a stop codon and
a 3´-UTR (clone p23-1). Northern blot analysis (see below) argues that the full-length protein is
much larger than that encoded by the cloned fragment. The complete open reading frame (ORF)
was PCR amplified as two overlapping fragments (see Material and Methods). The two PCR
products were used to reconstruct the full-length ORF, which was cloned into pBluescript SK+
and sequenced (GenBank accession # DQ860102). This sequence data shows that this ORF is
predicted to encode a protein of 1159 aa, and its C-terminus is identical to our Clone p23-1. We
have named this protein RAD51AP2 (RAD51 Associated Protein 2) (Fig. 1A). Comparing the
ORF sequence with the genomic sequence indicates that the RAD51AP2 ORF consists of three
exons, one very large one encoding 1,083 aa, followed by two much smaller ones encoding 27 aa
and 49 aa (Fig. 1B). Our DNA and predicted aa sequence data are completely consistent with a
GenBank hypothetic cDNA (XM_496545) and protein (XP_496545).
Sequence analysis of the mouse genome predicts a homologous protein of 976 aa (Genbank
XP_147640; the predicted cDNA XM_147640 maps to mouse chromosome 12). The sequence
alignment of the predicted human and mouse homologs indicates that the human protein has an
extra region of 154 aa in the middle of exon 1 (underlined in Fig. 1A). This extra region does not
appear to be an extra unexcised intron, since it does not have a sequence resembling the
consensus for a splice junction, and this extra 154 aa region is also present in the genomic
sequence of Pan troglodytes (chimpanzee) (data not shown). Even the Rattus novegicus genomic
sequence is only missing 45 of the 154 aa compared to the human protein. At the very C-
terminus the human and chimpanzee proteins also encode 11 aa that are not present in either the
mouse or rat protein. GenBank also contains a partial sequence of a Gallus gallus (chicken)
homolog that also appears to be missing the 11 aa at the C-terminus (Fig 6A).
The predicted 1159-aa sequence of human RAD51AP2 shows no significant overall
homology to any other protein in the GenBank, and has no apparent protein motifs, except for a
sequence Ala-xxxx-Gly-Lys-Ser in the C-terminus that resembles the Walker A-type nucleotide
binding motif (consensus Ala/Gly-xxxx-Gly-Lys-Thr/Ser), but RAD51AP2 lacks any obvious
Walker B motif. The mouse, rat and partial chicken RAD51AP2 homologs all lack any sequence
similar to a Walker A or B motif.  Although the human RAD51AP2 protein lacks any other
apparent protein motif, the C-terminal region does show some interesting properties.  This region
is positively charged: among the last 55 residues, there are 7 arginines, 5 lysines and 3 histidines,
with only a single negatively charged residue (glutamic acid).  In addition the C-terminal region
shares homology with RAD51AP1 (shown below).
RAD51AP2 gene expression occurs in meiotic tissue only
Northern analysis of RAD51AP2 gene expression was performed using a panel of human
mRNAs from various organs. A strong hybridization signal was detected only in testis, with no
signal present in thymus, spleen, prostate, uterus, colon, small intestine, and peripheral blood
leukocytes (Fig. 2). The size of the hybridizing transcript is ~ 4.2 kb, predicting a protein of
>1000 amino acid residues, which corresponds well to the size of the RAD51AP2 ORF described
above. The meiotic specificity of RAD51AP2 gene expression is supported by our PCR analysis,
as we were not able to amplify any RAD51AP2 sequences from cDNA sources other than adult
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4 additional fetal tissues (Fig. 3A-B, and unpublished data on adult brain, heart, kidney, liver,
lung, pancreas, placenta and skeletal muscle). No PCR product was observed with 7 human cell
lines (HEK293, SKOV-3, Saos2, A431, Du145, H1299 and MCF7) (data not shown). As a
control, a PCR product from the RAD51AP1/PIR51 transcript was amplified, and shown to be
present in each of these same human 16 adult tissues, 5 fetal tissues and 7 cell lines (Fig. 3C-E
and additional data not shown).  It should be noted that 35 PCR cycles were used to ensure that
even rare transcripts would be amplified.  This data can be used to determine if a transcript is
present in a sample, but can not be used to quantify the transcript level, if it is present.
Information about the expression of new genes can also be obtained by examining the
EST database at GenBank, which includes sequences from different cDNA libraries.  There are
currently only eleven human EST clones in the database with sequence identity to parts of
RAD51AP2. Six EST clones are from testis libraries, including three that appear to encode the
5´-end (Materials and Methods), and another EST clone was isolated from a germ cell tumor.
The remaining four are from the Athersys RAGE (random activation of gene expression) library
constructed by using specialized integration vectors that result in the artificial transcription of
even normally silenced genes (38). Therefore, data from the EST database is consistent with
expression of RAD51AP2 in testis and germ cells, with no expression in mitotic tissues. On the
other hand, the EST database has numerous RAD51AP1 EST clones from many different human
tissues, supporting the ubiquitous expression of this gene.
RAD51AP2 is not expressed in mitotic cells even after DNA damage
Although expression of RAD51AP2 was not observed in mitotic cells, it seemed possible that this
transcript might be induced by DNA damage. However, treatment of human U2OS cells with 2
Gy X-rays still resulted in no RAD51AP2 transcript (Fig. 3F-G), and the same result was also
observed using HeLa cells (data not shown).
Interaction of RAD51AP2 protein with RAD51 in the yeast two-hybrid system
The 321-aa RAD51AP2 fragment was subcloned from p23-1 into two-hybrid vectors as fusions
with the DNA-binding (DBD) and activation domain (AD) of Gal4, to reconfirm the interaction
with human RAD51 and to test for possible additional interactions. When fused to Gal4-AD,
RAD51AP2-C321 (containing the C-terminal 321 aa) showed strong and specific interaction
with RAD51 (Table 1). No interaction was observed with human DMC1 or the yeast RAD51
protein, both highly homologous to human RAD51, or with human RAD51AP1, another
interacting partner of RAD51. Also, no RAD51AP2-C321 interaction with human UBC9, lamin
C or mouse p53 protein was found (data not shown). The RAD51-interaction is mediated by the
extreme C-terminus of RAD51AP2-C321. The RAD51AP2-C321 protein in which the last 57
residues are deleted (designated as RAD51AP2-ΔC57) fails to interact with RAD51. In addition,
the last 92 amino acids of RAD51AP2 (C92) are sufficient for a strong interaction with RAD51,
although at only ~48% of the strength of the 321 aa fragment (Table 1). In light of our results on
RAD51AP2-ΔC57, it seems likely that the decreased strength of the RAD51AP2-C92 interaction
is due to reduced stability of this shorter fusion or masking of the interacting region, although we
can not rule out the possibility that additional residues outside of the last 92 aa of RAD51AP2
are necessary for full interaction with RAD51. When present as a fusion with Gal4-DBD in a
yeast reporter strain, the 321-aa RAD51AP2 polypeptide weakly activates transcription of lacZ
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the RAD51 interaction capability in the two-hybrid system and has no transcription activation
ability of its own, it was used in all subsequent two-hybrid studies as a Gal4-DBD fusion of
RAD51AP2. The original cloned 321-aa RAD51AP2 encoding sequence was used as a Gal4-AD
fusion.
The full length RAD51AP2 ORF and three long C-terminal fragments (C661, C830 and
C661) were also cloned into the Y2H vectors and tested for their interaction with human RAD51.
All four interacted with RAD51, although more weakly then the C-321 fragment, and the longer
the protein/fragment, the weaker the interaction (data not shown). Our favored interpretation of
this data is that the full-length 1,159 aa human RAD51AP2 protein is probably not stably
expressed at a very high level in yeast, and even the shorter fragments are not expressed well,
although better then the full-length protein. An alternative interpretation is that longer fragments
of RAD51AP2 contain regions that mask the interaction of RAD51AP2 with RAD51, at least in
the Y2H system. Full-length RAD51AP2 and the three truncations were also tested for
interaction with human DMC1, but no interaction was observed (data not shown).
Ectopically expressed RAD51AP2 interacts with RAD51 in human mitotic cells
To test if the RAD51-RAD51AP2 interaction could occur in vivo, the 293-aa RAD51AP2
polypeptide (RAD51AP2-C293) or its C-terminally truncated derivative (RAD51AP2-ΔC57),
both tagged with the T7 epitope, were transiently overexpressed in HEK293 cells, and
immunoprecipitation with anti-T7 antibody was carried out (Fig. 4A). A fraction of endogenous
RAD51 protein readily co-precipitated with RAD51AP2-C293, but not with RAD51AP2-ΔC57
or with a control protein (Fig. 4A, lanes 7-9). This result further stresses the importance of the
extreme C-terminus of RAD51AP2 for the interaction and provides evidence that when
recombinant RAD51AP2 is ectopically expressed in mitotic human cells it can associate with
RAD51.
Next, we asked whether the RAD51-RAD51AP2 interaction in human cells could be
modulated in response to DNA damage. To test this, RAD51AP2-C293 was transiently
overexpressed in HEK293 cells as described above, and DNA damage was introduced by adding
methyl methanesulfonate (MMS) or mitomycin C (MMC) 3 hours before harvesting cells for co-
IP analysis (Fig. 4B). Results from a number of experiments indicate that co-precipitation of
RAD51 with RAD51AP2-C293 is stimulated ~7- and ~17-fold by MMS or MMC treatment,
respectively (Fig. 4B, lanes 5-7; Fig. 4C). Previously, it was shown that these agents, at the
concentrations used, induce formation of nuclear RAD51 foci in a number of mammalian cell
lines, with up to 60% of cells being stained with anti-RAD51 antibody (39,40). These foci
presumably mark sites where RAD51-dependent repair of DNA damage takes place. In contrast,
cycloheximide, a protein synthesis inhibitor, does not induce RAD51 foci (40) and does not
affect significantly co-precipitation of RAD51 with RAD51AP2-C293 (Fig. 4B, lane 8; Fig. 4C).
Although DNA damage increases the interaction between these two proteins, we do not feel that
RAD51AP2 is involved in DNA repair since it is not expressed in mitotic cells (see Discussion).
RAD51AP2 and RAD51AP1 share a common carboxy-terminal motif necessary for
interaction with RAD51
Examination of the sequence of the RAD51AP2 carboxy-terminus revealed an intriguing
homology with RAD51AP1, a protein we previously isolated because of its interaction with
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amino acids located near the C-terminus of the two proteins (Fig. 5A), and in this region, 14
amino acids are identical between the two human proteins and 5 are highly conserved. The
region of strongest homology is the 16-aa C-terminal part of the region encompassing 11
identical and 3 highly conserved residues between RAD51AP1 and RAD51AP2.  It is important
to note that RAD51AP1 and RAD51AP2 are of very different sizes (335 aa and 1159 aa,
respectively) and that these proteins share not other regions of homology.
Deletion analysis was used to further map the region of RAD51AP2 responsible for the
interaction with RAD51 (Table 2). As mentioned above, deletion of the last 57 amino acids of
RAD51AP2 (RAD51AP2-ΔC57) completely eliminates interaction with RAD51 in yeast and
human cells. In contrast, the 92- and 33-aa C-terminal fragments of RAD51AP2 show strong
two-hybrid interaction with RAD51, in particular when fused to Gal4-DBD (Table 2). This result
indicates that a small region at the very end of the cloned RAD51AP2 sequence is its primary
site responsible for interaction with RAD51.
As shown above, RAD51AP2 is homologous in its C-terminus to RAD51AP1. Moreover,
we demonstrated previously that RAD51AP1 also interacts with RAD51 through its C-terminus
(37). To further define the region of RAD51AP1 involved in RAD51 binding, the C-terminal
fragments of RAD51AP1 analogous to those of RAD51AP2 were tested for their interaction with
RAD51. In particular, fragments RAD51AP1-C89 and RAD51AP1-C25 were used, which
roughly correspond to RAD51AP2-C92 and RAD51AP2-C33, respectively. As shown in Table
2, RAD51AP1-C89 and RAD51AP1-C25 protein fragments are highly efficient in their
interaction with RAD51. Both RAD51AP2-RAD51 and RAD51AP1-RAD51 interactions occur
when the inserts are in either orientation with regards to the Y2H vectors, but are strongest when
RAD51 is present as a Gal4-AD fusion.  Thus, RAD51AP2 and RAD51AP1 are both using short
sequences at their C-termini to bind to RAD51. This conclusion is further supported by our
mutational analysis of the RAD51AP2/RAD51AP1 homology region.
Conserved residues within the RAD51AP1 and RAD51AP2 C-terminal regions facilitate
interaction with RAD51
Site-specific mutagenesis of residues in the C-terminal domains of RAD51AP1 and RAD51AP2
was performed to determine whether the residues shared in common by these two proteins are
important for their interactions with RAD51.  Eight residues in RAD51AP1-CTD were mutated
(Fig. 5A), and four amino acid substitutions (R316A, L319Q, L328A and H329A) significantly
decreased the interaction with RAD51 in the Y2H system using both the qualitative X-gal assay
(data not shown) and the quantitative ONPG assay for β-galactosidase activity (Fig. 5B). In
addition, the double mutant RAD51AP1-H329A/P330A and the double L328/H329 deletion both
showed decreased interaction with RAD51 to a similar extent as the individual L328A and
H329A mutations in the qualitative assay (data not shown). Amino acid substitutions at other
residues did not affect the interaction with RAD51; the RAD51AP1-R321A and -K326A
substitutions in residues conserved with human RAD51AP2 each had no significant effect on
RAD51 interaction, nor did the RAD51AP1-L322S mutation in a residue not conserved with
RAD51AP2 (data not shown).
Amino acid substitutions in RAD51AP2 were made in three residues that are conserved
with RAD51AP1 and that greatly reduced the RAD51AP1-RAD51 interaction. In RAD51AP2,
these aa changes (RAD51AP2-L1134Q, -L1143A and -H1144A) all also greatly decreased the
interaction with RAD51 (Fig. 5C).  A stop codon replacing RAD51AP2-Y1146 also significantly
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decreased the interaction with RAD51, but to a much lesser extent. It seems reasonable to
speculate that the Tyr-Leu-Lys residues shared by human, mouse and chicken RAD51AP2 might
be important for full RAD51 interaction, although these residues are not conserved in
RAD51AP1.
Refined mapping of the region of human RAD54 that interacts with RAD51
Amino acid sequence comparisons of the shared RAD51-interacting motif (described above)
with the sequence of other RAD51-interacting partners revealed an interesting sequence
homology with human RAD54. In the most highly conserved region shared by RAD51AP1 and
RAD51AP2, out of 16 aa, RAD54 shares 50% homology (6 identical residues and 2 conserved
residues) (Fig. 6A). We have demonstrated previously that the human RAD54 protein interacts
with human RAD51 through sequences located within first 142 residues of RAD54 (16). The
region of RAD54 that shares homology with RAD51AP1-CTD and RAD51AP2-CTD is within
this previously defined RAD51-interacting region.
The homology of human RAD54 96-111 with the C-termini of RAD51AP2 and RAD51AP1
that facilitate the interaction with RAD51 (Fig. 6A) suggests that these residues within RAD54-
N142 may be critical for the interaction with RAD51. To test this, truncation mutations were
made from RAD54-N142. When tested in the Y2H system for interaction with RAD51, RAD54-
N89 gave between 25-32% as strong an interaction as full length RAD54-N142 (Fig. 6B and C).
Since RAD54-N89 does not contain any of the residues shared in common with RAD51AP1 and
RAD51AP2, it suggests that the conserved region is not required to obtain significant interaction
between RAD54 and RAD51. In addition, RAD54 90-142 that contains the complete conserved
region, failed to interact with RAD51 (Fig. 6B). On the other hand, there is some evidence that
this conserved region may play a role in increasing the interaction with RAD51.  For example,
RAD54-N118 fragment gave a much stronger interaction than RAD54-N89. In addition, a 40 aa
fragment (RAD54 79-118) that completely contains the conserved region gave ~43% of the
strength of the RAD51 interaction with RAD54-N142. Two larger fragments, each containing
RAD54 79-118, but each also including additional residues on one side or the other, both give
over 70%, as compared to RAD54-N142.  These results suggest that the core RAD51 interacting
region is RAD54 79-118, but that there are additional residues on each side that independently
and additively increase the strength of the interaction.
In addition, point mutations were introduced in RAD54 region 79-118, and analyzed in the
two-hybrid system (Fig. 6C). Amino acid substitutions (RAD54-L109Q and -H110A) in the very
conserved Leu-His motif did not affect the RAD54-RAD51 interaction at all, nor did a P112A
substitution (Fig. 6C). However, we found that residues N-terminal to the
RAD51AP1/RAD51AP2 homology region in RAD54 are important for the interaction with
RAD51, since RAD54-F82A and -P85A abolish the RAD51 interaction completely (Fig. 6C).
In summary, both RAD51AP2 and RAD51AP1 use a common sequence motif located near
their carboxy-termini for RAD51 binding. In contrast, a similar sequence motif present in the
amino-terminus of RAD54 protein is not completely critical for the interaction with RAD51.
Instead, residues closer to the amino-terminus of RAD54, such as F82 and P85 located outside of
the homologous region, seem to be essential for the interaction with RAD51.
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DISCUSSION
RAD51AP2 shares a conserved RAD51-binding motif with RAD51AP1
We isolated a fragment of a previously unknown protein, RAD51AP2, via its interaction with
human RAD51 in a yeast two-hybrid (Y2H) library screen (Fig. 1). The full length RAD51AP2
ORF was cloned and sequenced, and the sequence suggests that the full-length protein is 1159
amino acid residues with no significant homology to any other protein, apart from its C-terminal
RAD51-interacting region. We provided evidence that the interaction between RAD51AP2 and
RAD51 is facilitated by a short sequence at the C-terminus of RAD51AP2 (Table 1), which
displays strong homology (81% in a 16 aa region) to the C-terminal region of RAD51AP1 (Fig.
5A), a previously identified 335 aa RAD51-interacting protein (19,37). As with RAD51AP2, this
conserved motif in RAD51AP1 also comprises part of its interacting region with RAD51 (Table
2). Among the 16 aa spanning the highly homologous sequence motif between human
RAD51AP2 and RAD51AP1, 11 residues are identical and two are highly conserved. We have
not tested yet whether this highly homologous sequence motif (16 aa) is sufficient for either the
RAD51AP2-RAD51 or the RAD51AP1-RAD51 interaction. However, our Y2H results show
that the longer 25 residue-encompassing C-terminal region of RAD51AP1 and the last 33
residues in RAD51AP2 (inclusive of a stretch of residues with no homology to RAD51AP1 at
the very C-terminus – see Fig. 5A) are fully capable of interaction with RAD51. Interestingly, in
each gene, a relatively short C-terminal exon completely encodes the RAD51-interacting region,
and RAD51AP1 and RAD51AP2 share no other region of homology.
Our Y2H results on site-specific mutations in both RAD51AP1 and RAD51AP2
demonstrate that for both proteins several of the highly conserved residues are crucially
important to maintain the interaction with RAD51. To the best of our knowledge, RAD51AP1
and RAD51AP2 carry the first binding-motif for RAD51 that is commonly shared by more than
one of RAD51’s interacting partners. A somewhat similar situation exists for BRCA2 and its
multiple BRC repeats, since these repeats also bind to RAD51 via a conserved sequence motif
(20). However, the BRCA2-BRC repeat sequence does not appear to be present in any additional
RAD51-interacting partner, although it does share homology with a RAD51 self–interacting
region (22).
We speculate that both RAD51AP1 and RAD51AP2 may interact with the same region on
RAD51 via their commonly shared homologous sequence motifs. If this were the case, their
simultaneous binding to a single RAD51 monomer would be very unlikely. Since RAD51 forms
both multimers and filaments, it is still possible that RAD51AP1 and RAD51AP2 could
potentially bind to adjacent or nearby RAD51 monomers. As discussed below, RAD51AP2
appears not to be expressed in mitotic cells, but since RAD51, RAD51AP1 and RAD51AP2 are all
expressed in meiosis simultaneous interactions could still occur in meiotic cells.
At least twelve of the DNA replication- and repair-related protein partners that interact with
PCNA (proliferating cell nuclear antigen) also utilize a conserved motif, but different from the
RAD51-binding motif described here (41). In our study, a highly conserved RAD51-binding
motif has been identified, but it appears to be present in only two different human proteins
(RAD51AP1 and RAD51AP2), with the possible exception of RAD54 (discussed below). Unlike
the RAD51-binding motif, the PCNA-binding motif is ancient and conserved to archaea and
bacteriophages (41). Nonetheless, it still is possible that an ancestral RAD51- or RecA-binding
motif may exist that is related to the motif described here, but that the ancestral motif is
insufficiently conserved to be recognizable.
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RAD54 shares limited homology with the identified RAD51-binding motif
While attempting to identify other previously known partners of RAD51 that may carry a
sequence motif with some homology to the conserved motif in RAD51AP1/RAD51AP2, we
identified RAD54, which shares 50% homology within the 16 aa core region. Previously, we
already reported that the N-terminal region of human RAD54 (aa 1-142) facilitates binding to
RAD51 (16). Our sequence alignment (Fig. 6A) shows that aa 96-111, embedded within this N-
terminal region of RAD54, display significant homology to the conserved binding-motif in
RAD51AP1/RAD51AP2. However, the results from the Y2H experiments also suggest that
RAD54 aa 1-89 is sufficient to convey a strong interaction with RAD51 (Fig. 6B and C),
indicating that the residues with homology (aa 96-111) to the conserved RAD51-interacting
motif in RAD51AP1/RAD51AP2 are not required for the RAD54-RAD51 interaction. In
addition, two key residues in the N-terminal region of RAD54 located upstream of the
homologous region appear to be important for its interaction with RAD51 (Fig. 6B). Conversely,
several residues within the aa 96-111 region appear not to be involved in the RAD54-RAD51
interaction. However, when we analyzed truncated forms of RAD54 in the Y2H system we
obtained evidence that aa 96-111 may play a secondary role in enhancing the interaction between
RAD54 and RAD51 (Fig. 6B and C). Additionally, an extensive N-terminal domain of RAD54
appears to be required to obtain full interaction strength with RAD51 in the Y2H system (Fig.
6B). Our results suggest that the interaction between RAD54 and RAD51 may involve either a
large interface or a series of multiple shorter interfaces. RAD54 has been postulated to play an
important role in many stages of HRR (42), and its interaction with RAD51 in human cells is
very likely to be required for at least some of these activities.
The interaction between RAD51 and the N-terminal domain of RAD54 has also been
observed in the yeast S. cerevisiae (43,44). In recent in vitro experiments, the direct RAD51-
RAD54 interaction has been shown to be important for RAD54 enhancing the DNA pairing
reaction mediated by RAD51 (45). This paper also reported that RAD51 stimulates both the
RAD54 ATPase activity and the ability of RAD54 to introduce superhelical tension into circular
plasmid DNA, and that these activities are also depend on the RAD51-RAD54 direct interaction.
This recent study also showed that there are separable epitopes in RAD54 that interact with
RAD51, in accord with our speculations for an extensive RAD51-RAD54 interface (see above).
In our study however, the region of homology between human RAD54 and both RAD51AP1 and
RAD51AP2 does not appear to be a separable interacting epitope in RAD54, since RAD54 aa
90-142 includes the entire homologous region but does not by itself interact with human RAD51
(Fig. 6B). It is worth noting that the yeast RAD54 protein actually shares two different regions
with homology to the RAD51-interacting region of human RAD54.  One region of ScRAD54 (aa
37-50, TKPFRVPYKNTHIP) shares homology only with the HsRAD54 region that includes F82
and P85 (underlined F40 and P43 in ScRAD54), while the second region of ScRAD54 (aa 129-
164, RSFTVPIKGYVQRHSLPLTLGMKKKITPEPRPLHDP) shares homology with both the
F82/P85 region and the region with homology with RAD51AP1 and RAD51AP2 (our
unpublished analysis).
The RAD51AP2 protein appears to be a meiotic partner of RAD51
Among the 16 adult and 5 fetal tissues tested, we found that the RAD51AP2 gene is expressed
only in adult testis and fetal ovary (Fig. 2 and 3), indicating that RAD51AP2 is a likely meiosis-
specific partner of RAD51. No expression was observed in adult ovary, where cells are arrested
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in meiosis after recombination has been completed, nor was expression observed in fetal testis,
where cells have not yet initiated meiosis. In addition, analyzing the enormous human EST
database, no human RAD51AP2 EST clones have been identified from non-meiotic tissue,
confirming our observation that RAD51AP2 seems to be expressed only in cells undergoing
meiosis. We also tested if RAD51AP2 might be expressed in mitotic cells after DNA damage,
but we found no such expression (Fig. 3F). This was not unexpected, since even those DNA
repair genes induced by DNA damage are normally constitutively expressed at a detectable level.
It is virtually impossible to prove that RAD51AP2, or any gene for that matter, is never expressed
in any mitotic human cells, but our data strongly supports this view.
Although RAD51AP2 does not appear to be expressed in mitotic cells, our data show that an
ectopically expressed recombinant RAD51AP2 fragment is capable of interacting with
endogenous RAD51 in vivo (Fig. 4). In addition, this interaction is stimulated ~7- and ~17-fold
after exposure to the DNA-damaging agents MMC and MMS, respectively. Both exposure to
MMC and to MMS produces DSBs that are repaired by HRR mediated by RAD51, and DSBs
also are produced endogenously during DNA replication and during meiosis (7,8,12,36). The
increase in the RAD51AP2-RAD51 association after DNA damage may occur if both proteins
are targeted to the same locations within the nucleus, e.g.  DSBs and/or RAD51 foci.
Alternatively, or concomitantly, the RAD51-RAD51AP2 interaction may also be stabilized via
posttranslational protein modification in response to high levels of DNA damage. If RAD51AP2
is expressed only during meiosis, as seems likely from our data, DNA damage may mimic some
aspect of meiosis such as the formation of DSBs, and if this is the case, then RAD51AP2 may
preferentially interact with RAD51 when DSBs are present during pachytene (6-8). Studying the
interactions of an ectopically overexpressed protein in mammalian cells can sometimes lead to
false positives, but we feel that this is not likely to be the case here. Firstly, the in vivo interaction
studies confirm a protein-protein interaction observed in the Y2H system that is very strong and
that occurs when the inserts are in both orientations. Secondly, it seems rather unlikely that a
false-positive protein-protein interaction would be stabilized by DNA damage, as was observed
here.
Interestingly, the isolated RAD51AP2 amino acid sequence does not interact in the Y2H
system with DMC1, a homolog of RAD51 that is meiotic specific (6-8) and required for meiotic
chromosome synapsis (46,47). The interaction of RAD51AP2 with other meiotic-specific
proteins, such as the SPO11 endonuclease and proteins involved in the synaptonemal complex,
has not been tested, but would be worth testing.
RAD51-associated proteins frequently play an important role in recombination
Much has been learned recently about RAD51 function and regulation by studying its interacting
partners.  For example, the interaction of RAD51 with TP53 has been shown to control the
specificity of RAD51 in HRR (23). The interaction of RAD51 with the BRCA2-BRC repeats
have been postulated to play a role in aligning multiple monomers of RAD51 and then
polymerizing them into a filament on ssDNA (48). RAD51 interacts with a DNA-binding
domain of RPA, and this interaction has been postulated to help RAD51 displace RPA from
ssDNA (33). Eventually understanding the  function and structure of the interactions of RAD51
with RAD51AP1 and with RAD51AP2 should give us important information about HRR,
meiotic recombination, and the role of these new proteins.
In conclusion, RAD51AP2 has been identified as a novel meiotic-specific RAD51-
interacting protein, and RAD51AP2 and RAD51AP1 share a common motif important for
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RAD51 binding.  The fact that RAD51AP1 and RAD51AP2 are both vertebrate-specific suggest
that these proteins may potentially play a regulatory role in recombination.
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Figure Legends
Figure 1. Sequence of the human RAD51AP2 proteins and structure of the human RAD51AP2
gene. (A) The amino acid sequence of the entire human RAD51AP2 proteins predicted from our
RAD51AP2 cDNA sequence (GenBank accession # DQ860102). Residues similar to a Walker
A-type nucleotide-binding motif in human RAD51AP2 are in the gray box. The long underlined
region is missing in the mouse homolog, and the two short underlined regions are the boundaries
between the amino acids encoded by the 3 exons. (B) Comparing the cDNA sequence we have
determined with the genomic sequence in GenBank, it was determined that RAD51AP2 consists
of one very long exon followed by two short exons, the last of which completely encodes the
RAD51-interacting domain.
Figure 2. Northern blot analysis of the RAD51AP2 gene in human tissues. Lanes contain ~2 µg
of poly A+ RNA from the human tissues indicated. PBL, peripheral blood leukocytes; SI, small
intestine. Upper panel, hybridization with RAD51AP2 cDNA probe. Lower panel, hybridization
with human β-actin cDNA probe. The positions of RNA size markers, in kilobases, are indicated
on the right.
Figure 3. PCR analysis showing meiotic-specific expression of human RAD51AP2 in adult testis
and fetal ovary, but ubiquitous expression of RAD51AP1. (A ) RAD51AP2 (AP2 in figure)
transcript in human adult tissues (note: RAD51AP2 is top band in testis sample only and PCR
primers are the bottom bands). LC - leukocytes, SI - small intestine. (B) RAD51AP2 transcripts
in human fetal tissues. (C and D) RAD51AP1 (AP1 in figure) transcript in human adult tissues.
SM – smooth muscle. (E) RAD51AP1 transcripts in human fetal tissues. Note: RAD51AP1 has
multiple variants in adult testis and fetal ovary. (B – E) DNA size markers (400 and 800 bp) in
right lane. (F) RAD51AP2 transcript is not induced in U20S cells exposed to 2 Gy X-rays. End-
point RT-PCR was carried out from 1st strand cDNA samples in a multiplex PCR reaction
amplifying both a 838 bp product for β-actin and a 536???? bp product for RAD51AP2 (as in A
and B). A product for RAD51AP1 was not obtained (as indicated by black arrow head). (G)
Same samples as in F: End-point RT-PCR for β-actin and GADD45A (positive control for the
induction of transcript after X-rays).
Figure 4. RAD51AP2 and RAD51 proteins interact in human cells, and the interaction is
enhanced by DNA damage. (A) Human HEK293 cells were transiently transfected with plasmids
encoding the following T7 epitope-tagged proteins: Vmw65 protein of herpesvirus (lane 1); 293-
aa RAD51AP2 polypeptide (lane 2); RAD51AP2 protein deleted for its last 57 residues (lane 3).
Immunoprecipitation with anti-T7 antibody followed by protein A-agarose beads was carried
out, and fractions of cell lysates before IP, supernatant of IP, and IP pellets were analyzed by
Western blotting using anti-T7 (top panel) or anti-RAD51 antibody (lower panel). Secondary
antibodies were conjugated to alkaline phosphatase, which was detected using chromogenic
substrates. (B) Transfection with plasmid encoding the 293-aa RAD51AP2 polypeptide was
performed as in panel A, and 0.5 µg/ml MMC, 100 µg/ml MMS or 10 µg/ml cycloheximide
(Cyc.) was added to individual cultures 3 hrs before harvesting cells for IP. IP and Western
blotting were done as in panel A, except that chemiluminescent substrates were used to detect
peroxidase conjugated to secondary antibodies.  To facilitate the relative comparison of RAD51
signals from IP pellets (shown in panel C), the amount of these fractions loaded on the gel was
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adjusted in an effort to get similar intensities of the T7-tagged RAD51AP2 signal in each lane.
The residual differences were normalized to the control (untreated cells) for comparison of the
amounts of RAD51 that coprecipitated with RAD51AP2. (C.) Quantitation of RAD51-
RAD51AP2 coimmunoprecipitation from panel B. The signals from precipitated RAD51 in IP
pellet fractions were measured using a densitometer and then normalized for the signal from anti-
T7 analysis of the same fractions. The relative increase of RAD51 signal from treated cells over
the signal observed from untreated cells (artificially set at 1.0 in left lane) is shown.
Figure 5. Sequence homology between the RAD51AP2 and RAD51AP1 and mutational analysis
of their shared RAD51-interacting motifs. (A) Amino acid identities and similarities are
indicated by dark blue and light gray squares, respectively. The complete final exons of human
RAD51AP1 (exon 9; aa 292-335) and of human RAD51AP2 (exon 3; aa 1111-1159) are shown.
Under the sequences are the original residues that were mutated by site-directed mutagenesis.
The underlined mutated residues significantly reduce the interaction with RAD51 (see panels B
and C).  Species abbreviations are as follows: Hs – Homo sapiens; Mm – Mus musculus; Gg –
Gallus gallus. (B) Interactions in the Y2H system between RAD51 (i.e. pEG960) and both
RAD51AP1 (i.e. pOK31, with all of RAD51AP1) and site-specifically mutated RAD51AP1 (in
pOK31). Results are the average from three different colonies, with the standard error of the
mean. (C) Interactions in the Y2H system between RAD51 (i.e. pEG960) and both RAD51AP2
(i.e. pDS439; pGBKT7-RAD51AP2-C33) and site-specifically mutated RAD51AP2 (in
pDS439). Results are the average from two different colonies, with the standard error of the
mean. Please note: the Y190-ura- Y2H strain was used in these studies, and it gives lower β-
galactosidase activity that the HF7c Y2H strain used in Tables 1 and 2, and in addition, the
RAD51AP2-C33 construct is in the pGBKT7 vector that also results in lower β-gal activity than
similar pGBT9-derived constructs. The negative control was the original empty vector used for
that construct, together with RAD51.
Figure 6. Truncation mapping and mutational analysis of the human RAD54-RAD51
interaction. (A) Amino acid sequence homology between human RAD54 and the RAD51-
interacting domains of RAD51AP1 and RAD51AP2. Amino acid identities and similarities are
indicated by dark blue and light gray squares, respectively. Under the sequences are the original
RAD54 residues that were mutated by site-directed mutagenesis. (B) PCR was used to make
different truncation constructs of RAD54-N142 (aa 1-142) in pGBT9, and these truncations were
tested for interaction with RAD51 (pEG960) in the Y2H strain Y190-ura-. Results are the
average from three different colonies, with the standard error of the mean shown. Only one
colony of the negative control (pGBT9 with pEG918) was quantified, but similar negative
controls always give about this same result. (C) Mutations were introduced into the N-terminal
fragments of RAD54 consisting of 142 or 89 residues (N142 and N89, respectively) and tested
for their interaction with RAD51 in the two-hybrid system, using Y2H strain HF7c. The P85A
mutation was made in RAD54-N89, while all the rest were made in RAD54-N142. WT,
wild-type sequence. For identical constructs, the Y2H strain Y190-ura- gives lower β -
galactosidase activity that HF7c.
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Table 1. Specific interaction of RAD51AP2 with RAD51 in the two-hybrid system is
mediated by the carboxy-terminus of RAD51AP2.
____________________________________________________________________
Gal4 DBD* Gal4 AD Gal4 DBD      Gal4 AD Units of
plasmid plasmid protein fusion      protein fusion β-galactosidase
____________________________________________________________________
pEG918 pOK42 RAD51 RAD51AP2-C321 300.9
pOK21  pOK42 DMC1 RAD51AP2-C321 <0.3
pEG978 pOK42 ScRAD51 RAD51AP2-C321 <0.3
pOK31  pOK42 RAD51AP1 RAD51AP2-C321 <0.3
pEG918 pOK77 RAD51 RAD51AP2-ΔC57** <0.5
pEG918 pOK40 RAD51 RAD51AP2-C92 143.4
____________________________________________________________________
* DBD and AD stand for the DNA-binding and activation domain of Gal4, respectively. The units of β-
galactosidase are average values from at least four liquid cultures. All inserts are human except
ScRAD51, which is from yeast.
** This plasmid actually only encodes the C321 fragment deleted for the last 57 aa, and similarly in Table
2.
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Table 2. Carboxy-terminal fragments of RAD51AP2 and RAD51AP1 proteins
interact with RAD51.
___________________________________________________________________
Gal4 DBD Gal4 AD Gal4 DBD Gal4 AD Units of
plasmid plasmid protein fusion  protein fusion β-galactosidase*
___________________________________________________________________
pEG918 pOK42  RAD51 RAD51AP2-C321 300.9
pEG918 pOK77  RAD51 RAD51AP2-ΔC57  <0.5
pEG918 pOK40  RAD51 RAD51AP2-C92 143.4
pOK76  pEG960 RAD51AP2-C92 RAD51 521.0
pOK92  pEG960 RAD51AP2-C33 RAD51 395.4
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
pEG918 pOK18  RAD51 RAD51AP1 111.0
pEG918 pOK35  RAD51 RAD51AP1-C89  24.6
pOK31  pEG960 RAD51AP1 RAD51 590.3
pOK62  pEG960 RAD51AP1-C89 RAD51 419.6
pOK81  pEG960 RAD51AP1-C25 RAD51 473.3
___________________________________________________________________
* The units of β-galactosidase are average values from at least four liquid cultures.
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